Background
==========

Cancer is among the leading causes of death in both developed and developing countries,[@b1-ott-11-449] with early detection and treatment remaining the best strategy to improve prognosis and quality of life. Although many studies have tried to identify biomarkers for these purposes in various human cancers, their success has been limited. Thus, effective novel biomarkers remain a topic of great clinical interest.[@b2-ott-11-449]

Breast cancer is the most common malignancy and the leading cause of death from cancer among women worldwide.[@b3-ott-11-449] Although several prognostic markers exist for breast cancer, only a few are clinically useful in humans. Therefore, additional models and therapeutic targets are being developed to improve our understanding of the biology of human breast cancer and help with the development of novel treatment options.[@b4-ott-11-449] Recent advances in our knowledge of apoptosis control, cell proliferation, tumor progression, and differentiation pathways have improved our understanding of the mechanisms underlying breast cancer progression.

*EZH2* is a catalytic subunit of the epigenetic regulator polycomb repressive complex 2 (PRC2) located on chromosome 7q35.[@b5-ott-11-449]--[@b8-ott-11-449] PRC2, which includes *EZH2* suppressor of zeste 12 (SUZ12), and embryonic ectoderm development, is responsible for trimethylating histone 3 lysine residue 27 (H3K27).[@b4-ott-11-449],[@b9-ott-11-449] Several articles have implicated *EZH2* in cell proliferation, invasion, apoptosis, angiogenesis, metastasis, stem cell maintenance, drug resistance, and disease progression in cancer.[@b2-ott-11-449],[@b10-ott-11-449]--[@b12-ott-11-449] Moreover, *EZH2* overexpression and mutations have been found in a wide range of human tumors, including breast, prostate, ovarian, lung, gastric, colon, urogenital tract (including uterine, urinary bladder, renal cell carcinoma, kidney, and renal cell cancer), brain, endometrial, hematological, head and neck (squamous cell carcinoma), liver, and pancreatic biliary cancers, as well as lymphomas, melanomas, and sarcomas.[@b2-ott-11-449],[@b4-ott-11-449],[@b9-ott-11-449],[@b11-ott-11-449]--[@b15-ott-11-449]

In breast cancer, *EZH2* overexpression is often associated with more advanced disease, higher histologic grade, increased tumor cell proliferation, lymph node invasion, larger tumor size, metastasis, and inferior overall survival (OS) and disease-free survival (DFS).[@b12-ott-11-449]--[@b14-ott-11-449] Some study results also showed that *EZH2* overexpression was associated with larger tumor size, advanced disease, and significantly reduced DFS and OS, but added that it was associated with estrogen receptor (ER)-negative and progesterone receptor (PR)-negative status.[@b6-ott-11-449],[@b10-ott-11-449],[@b12-ott-11-449] Although Reijm et al reported that there was no significant association between *EZH2* protein expression and menopausal status, tumor histology, or PR status, they found significant positive associations with the number of lymph nodes involved, the histologic grade, and the human epidermal growth factor receptor 2 (HER2) status.[@b13-ott-11-449] In patients with breast cancer, Bachmann et al reported that high *EZH2* expression was associated with high histologic grade, locally advanced cancer, and distant metastasis.[@b16-ott-11-449]

The association of *EZH2* expression with clinicopathologic features such as PR status, HER2 expression, nuclear grade, and proliferative index is inconsistent in the existing literature. To evaluate the clinicopathologic significance of *EZH2* expression in breast cancer, we therefore examined the correlations between changes in *EZH2* expression and important clinical variables (ie, ER, PR, HER2, Ki-67, P53, DFS, and OS).

Materials and methods
=====================

We analyzed the surgical specimens of primary breast tumors from patients who underwent surgery at Tabriz University of Medical Sciences, Tabriz, Iran, between April 2009 and February 2017. The study protocol was approved by the ethics committee of Tabriz University of Medical Sciences (Permit no 5/d/988072). All the patients signed a consent form during hospitalization and referring to our clinic, to allow us review their medical records and tissue sample slides, for any future studies.

In all the cases, we retrieved archived slides of breast tumor tissue stained with hematoxylin and eosin and reviewed them to confirm pathological features based on the 2012 World Health Organization classification.[@b17-ott-11-449] Suitable tissue blocks were identified for immunohistochemical (IHC) analysis, and we constructed tissue microarrays using the collected tissue. We performed pathologic TNM classification and staging for all the cases, using the seventh edition of the American Joint Committee on Cancer criteria.[@b18-ott-11-449] The histologic grade of invasive breast carcinoma was graded according to the breast carcinoma classification of the World Health Organization.[@b17-ott-11-449]

IHC analysis
------------

IHC staining was performed in all the cases for ER, PR, HER2, Ki-67, P53, and *EZH2* biomarkers. For histologic study, tumor samples were fixed in 10% buffered formalin and embedded as paraffin blocks. The sections were stained by hematoxylin and eosin, and histologic grading was done according to the Bloom and Richardson criteria, as modified in previous studies.[@b17-ott-11-449]--[@b19-ott-11-449] This grading methodology is based on the sum of the degree of tubule formation, nuclear pleomorphism, and mitotic activity.

Sections for IHC analysis were deparaffinized through graded alcohols and xylene, placed in an EDTA buffer solution (pH 9.0), and then heated to 100°C in a microwave oven at 900 W for 2--5 minutes and 180 W for 5 minutes until boiling. Then, the slides were left in the solution to cool down at room temperature for \~15 minutes and were rinsed in tris-buffered saline (pH=7.6) for 5 minutes. Endogenous peroxidase with 3% hydrogen peroxidase in methanol was added for 10 minutes to block nonspecific binding, and then the slides were incubated with the primary antibodies overnight in 4°C. The following primary antibodies were used: ER (clone ID5; Dako Denmark A/S, Glostrup, Denmark), PR (clone PgR636; Dako Denmark A/S), Ki-67 (cloneMIB-1; Dako Denmark A/S), P53 (cloneD07; Dako Denmark A/S), HER/2neu (REF: A0485, 1/200; Dako Denmark A/S). Then, the slides were incubated in EnVision for 30 minutes and, after rinsing in tris-buffered tween for 5 minutes, were incubated with chromogen for a further 5 minutes. Finally, the slides were rinsed in tris-buffered saline, counterstained with hematoxylin, and dehydrated with alcohols (96% and 100%) and xylene before being sealed with a cover slip. For *EZH2* antibody, we used 1.15 diluted phosphate-buffered saline solution.

The criteria of assessment of the proportion and intensity of staining in our study was as follows:[@b19-ott-11-449]

Score of proportion: 0=no staining1=\<1% nuclei staining2=1%--10% nuclei staining3=11%--33% nuclei staining4=34%--66% nuclei staining5=67%--100% nuclei staining

Score of intensity: 0= no staining1= weak staining2= moderate staining3= strong staining.

The total score of proportion and intensity was the final score of expression. The positive *EZH2* staining was in brown and within the nuclei. Low scores (range 0--4) were classified as indicating low *EZH2* expression, and high scores (range 5--8) were classified as indicating high *EZH2* expression ([Figure 1](#f1-ott-11-449){ref-type="fig"}). ER, PR, Ki-67, P53, and HER2 statuses were determined by IHC analysis.

Clinical outcome assessment
---------------------------

After surgery, all patients were followed up every 4--6 months for the first 5 years and every 12 months thereafter. OS was defined as the time from the date of surgery to the date of death from breast cancer or the date of last follow-up if patients were still alive. DFS was measured from the date of surgery to local recurrence or distant metastasis, date of death, or the last recorded date.

Statistical analysis
--------------------

Descriptive data were analyzed using IBM SPSS Version 17 (IBM Corporation, Armonk, NY, USA). Simple and multiple logistic regression analyses were performed to calculate the unadjusted and adjusted hazard ratios (HRs) with their 95% CIs. *EZH2* expression was used as the dependent variable and *P*-values ≤0.05 were considered statistically significant in all analyses. For the survival analyses, the OS and DFS were defined as the time from date of surgery to the date of death and relapse, respectively. The Kaplan--Meier method, with the log-rank test, was used to assess statistical significance. Finally, the Cox proportional hazard method was used to evaluate the relationship between *EZH2* expression and the independent variables (ie, ER, PR, Ki-67 P53, and HER2 status) on OS and DFS.

Results
=======

We included 100 patients with breast cancer (mean age 51.05±9.54 years, range 34--75 years); their clinicopathologic characteristics are shown in [Table 1](#t1-ott-11-449){ref-type="table"}. Patients received multimodal therapy, including adjuvant chemotherapy, surgery, and radiation therapy, and patients with HER2-positive tumors were also given adjuvant trastuzumab. All patients with hormone receptor-positive cancers received tamoxifen or an aromatase inhibitor.

Correlation coefficients for clinicopathologic characteristics and *EZH2* expression (Spearman's correlation analyses)
----------------------------------------------------------------------------------------------------------------------

ER (*r*=−0.173, *P*=0.084), PR (*r*=−0.136, *P*=0.179), Ki-67 (*r*=−0.081, *P*=0.421), P53 (*r*=−0.135, *P*=0.181), and HER (*r*=0.134, *P*=0.183) statuses were not significantly correlated with *EZH2* expression in the breast cancer tissue. Other clinicopathologic characteristics did not correlate with *EZH2* expression.

Associations between *EZH2* expression and clinicopathologic characteristics
----------------------------------------------------------------------------

The associations between *EZH2* expression and clinicopathologic characteristics are shown in [Table 2](#t2-ott-11-449){ref-type="table"}. High *EZH2* expression was significantly correlated with lymph node status (*P*\<0.05). Age, menopausal status, tumor size, metastatic status, histologic grade, lymphovascular invasion status, operation status, ER status, PR status, HER2 status, Ki-67 expression, and p53 expression did not correlate with *EZH2* expression.

In the univariate analyses, *EZH2* expression was significantly associated with lymph node status only (HR 8.44, 95% CI 3.056--23.3, *P*\<0.05). After adjustment for prognostic factors, multivariate analysis revealed that no factors were associated with *EZH2* expression ([Table 3](#t3-ott-11-449){ref-type="table"}).

Survival analysis and association of *EZH2* expression and patient outcome
--------------------------------------------------------------------------

The median follow-up period for all patients was 1,250 days. At the time of analysis, there were 8 and 13 deaths suitable for inclusion in the OS and DFS analyses, respectively. The mean OS rates of patients with high and low *EZH2* expression were 655 days (95% CI 407.55--902.44) and 787.5 days (95% CI 0--1,615.6), respectively (log-rank Mantel--Cox *P*=0.336; [Figure 2A](#f2-ott-11-449){ref-type="fig"}). The mean DFS rates for high and low *EZH2* expression were 487.27 days (95% CI 296.07--678.48) and 908.5 days (95% CI 362.64--1,454.36), respectively (log-rank Mantel--Cox *P*=0.18; [Figure 2B](#f2-ott-11-449){ref-type="fig"}). *EZH2* expression was not associated with either the OS or the DFS (*P*=0.4). By contrast, Cox proportional hazard regression showed that lymphatic invasion was significantly associated with poor DFS (HR 0.007, 95% CI 0.00--0.43, *P*\<0.05). Multivariate analysis confirmed that there was no significant association between *EZH2* expression and either the DFS (HR 3.69, 95% CI 0.46--29.39, *P*=0.217) or the OS (HR 2.75, 95% CI 0.32--23.50, *P*=0.35) ([Figure 2](#f2-ott-11-449){ref-type="fig"}; [Tables 4](#t4-ott-11-449){ref-type="table"} and [5](#t5-ott-11-449){ref-type="table"}).

Discussion
==========

In this study, we evaluated *EZH2* expression in 100 breast cancer specimens, identifying that expression was high in 74 patients and low in 26 patients. Consistent with research by Reijm et al,[@b13-ott-11-449] we confirmed that there was no significant association between *EZH2* expression and menopausal status, tumor histology, and ER, PR, Ki-67, or P53 status. In another study, however, Inari et al showed that metastatic lesions exhibited significantly higher levels of Ki-67 expression (75.0% vs 57.3%, *P*=0.010) and *EZH2* (82.3% vs 56.3%, *P*\<0.0001) compared with primary lesions.[@b6-ott-11-449] Therefore, the lack of a significant association between *EZH2* and Ki-67 expression in our study may have been because most patients had nonmetastatic disease.

Consistent with the research by Reijm et al,[@b13-ott-11-449] the present study also showed that high *EZH2* expression was associated with the lymph node status. However, this association was only significant in the univariate analysis (HR 8.44, 95% CI 3.056--23.3, *P*\<0.05). By contrast, the associations between *EZH2* and the other clinicopathologic characters did not reach statistical significance.

The potential association between *EZH2* and HER2 remains controversial. Collett et al and Holm et al each found a high abundance of *EZH2* in HER2-positive breast tumors.[@b20-ott-11-449],[@b21-ott-11-449] In contrast, no association was found in either this study or that by Kleer et al,[@b22-ott-11-449] which may be due to the small number of patients with HER2-positive tumors in our samples. This should be reviewed in a study with a larger sample size.

Recently, Bae et al and Jang et al reported that high *EZH2* expression was a prognostic factor for shorter OS in patients with breast cancer.[@b23-ott-11-449],[@b24-ott-11-449] Therefore, we examined the association of *EZH2* expression with OS and DFS. Although we showed that the mean OS and DFS were shorter in patients with high *EZH2* expression than in patients with low *EZH2* expression, there was no statistically significant association between the survival rates. This is probably due to the difference in the number of patients and the short follow-up period between our studies. Differences in the *EZH2* scoring system can also contribute to this issue, indicating that there is a need to develop a uniform scoring system to help compare research in the future.

Breast cancer is the most common malignancy and the leading cause of cancer-related death among women worldwide.[@b3-ott-11-449],[@b24-ott-11-449] Moreover, based on reports published by the Iranian Cancer Registry in 2009, breast cancer was the most common cancer in females in Iran and accounted for a massive 24.6% of all cases of cancer.[@b25-ott-11-449] Between 2005 and 2010, there was an increase in the age-standardized incidence rate for breast cancer from 23.1 to 28.3 per 100,000 women.[@b25-ott-11-449],[@b26-ott-11-449] According to the most recent data of the Population Based Cancer Registry of East Azerbaijan, there were \~683 new breast cancer cases, with an age standardized incidence rate of 31 per 100,000 women in the East Azerbaijan province. Given the local prevalence of breast cancer, and the lack of research in Iran, our research might also illuminate the clinicopathologic characteristics of breast cancer specific to our region.

This study has some limitations. First, we analyzed a small number of cases and cannot exclude the possibility of selection bias. Second, the study had a short follow-up period for determining survival compared with other studies on this topic, making it difficult to assess the impact of *EZH2* expression on disease progression and death. Third, *EZH2* scoring was performed in-house, whereas previous studies have used different *EZH2* scoring methods; it is therefore possible that the differences among the scoring methods accounts for the lack of comparability in some of the results. Despite these limitations, our study benefits from having evaluated a series of breast cancers from a single institution, as well as from having immunohistochemically analyzed *EZH2* expression, Ki-67 proliferation, HER2 overexpression, ER status, and PR status.

Conclusion
==========

We showed a significant association between *EZH2* and lymph node status but failed to show any significant associations between *EZH2* and other clinicopathologic characteristics. Also, increased *EZH2* expression was not associated with poor OS or DFS in patients with breast cancer. However, to the best of our knowledge, this is the first study to have evaluated the association of *EZH2* and clinicopathologic characteristics in the north west of Iran. Overall, our results indicate that *EZH2* expression might be a useful marker of poor prognosis.
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![Immunohistochemical analysis of *EZH2* in breast cancer (×400).\
**Note:** (**A**) Hemotoxylin and eosin stain, (**B**) high expression, and (**C**) low expression.](ott-11-449Fig1){#f1-ott-11-449}

![Kaplan--Meier curves showing association of *EZH2* expression in patients with breast cancer. (**A**) Overall survival (*P*=0.336) and (**B**) disease-free survival (*P*=0.18).](ott-11-449Fig2){#f2-ott-11-449}

###### 

Clinicopathologic characteristics of patients with breast cancer

  -------------------------------------------------------------
  Prognostic factors                   Patients\   Frequency\
                                       (n=100)     (%)
  -------------------- --------------- ----------- ------------
  Age                  ≤50 years       46          46

  \>50 years           54              54          

  Menopausal status    Premenopausal   71          71

  Postmenopausal       29              29          

  Operation method     MRM             72          72

  BCS                  28              28          

  Histologic grade     1               13          13

  2                    60              60          

  3                    12              12          

  Vascular invasion    Positive        79          79

  Negative             21              21          

  Lymphatic invasion   Positive        34          34

  Negative             66              66          

  Lymph node status    Positive        63          63

  Negative             37              37          

  Tumor size           \<2 mm          13          13

  2--5 mm              72              72          

  ≥5 mm                15              15          

  Stage                I               13          13

  II                   60              60          

  III                  12              12          

  IV                   15              15          

  ER expression        Positive        86          86

  Negative             14              14          

  PR expression        Positive        89          89

  Negative             11              11          

  Ki-67 expression     Positive        47          47

  Negative             53              53          

  P53 expression       Positive        58          58

  Negative             42              42          

  HER2 expression      Positive        16          16

  Negative             84              84          

  *EZH2* expression    Low             26          26

  High                 74              74          
  -------------------------------------------------------------

**Abbreviations:** MRM, modified radical mastectomy; BCS, breast-conserving surgery; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; *EZH2*, enhancer of zeste homolog 2.

###### 

*EZH2* expression in breast cancer and relationship with clinicopathologic characteristics

  Prognostic factors                   *EZH2*, N (%)   *P*-value   
  -------------------- --------------- --------------- ----------- -------
  Age                  ≤50 years       9 (19.6)        37 (80.4)   0.1
  \>50 years           17 (31.3)       37 (68.5)                   
  Menopausal status    Premenopausal   17 (23.9)       54 (76.1)   0.4
  Postmenopausal       9 (31)          20 (69)                     
  Operation method     MRM             14 (19.4)       58 (80.6)   ≤0.05
  BCS                  12 (42.9)       16 (57.1)                   
  Histologic grade     1               5 (41.7)        7 (58.7)    0.3
  2                    20 (24.7)       61 (75.3)                   
  3                    1 (14.3)        6 (85.7)                    
  Vascular invasion    Positive        21 (26.6)       58 (73.4)   0.7
  Negative             5 (23.8)        16 (76.2)                   
  Lymphatic invasion   Positive        7 (20.6)        27 (79.4)   0.3
  Negative             19 (28.8)       47 (71.2)                   
  Tumor size           \<2 mm          3 (23.1)        10 (76.9)   0.9
  2--5 mm              19 (26.4)       53 (73.6)                   
  ≥5 mm                4 (26.7)        11 (73.3)                   
  Lymph node status    Positive        7 (11.1)        56 (88.9)   ≤0.05
  Negative             19 (51.4)       18 (48.6)                   
  Stage                I               3 (23.1)        10 (76.9)   0.8
  II                   17 (28.3)       43 (71.7)                   
  III                  2 (16.7)        10 (83.3)                   
  IV                   4 (26.7)        11 (73.3)                   
  ER expression        Positive        25 (29.1)       61 (70.9)   0.08
  Negative             1 (7.1)         13 (92.9)                   
  PR expression        Positive        25 (28.1)       64 (71.9)   0.1
  Negative             1 (9.1)         10 (90.9)                   
  Ki-67 expression     Positive        14 (29.8)       33 (70.2)   0.4
  Negative             12 (22.6)       41 (77.4)                   
  P53 expression       Positive        18 (31.0)       40 (69.0)   0.1
  Negative             8 (19.0)        34 (81.0)                   
  HER2 expression      Positive        2 (12.5)        14 (87.5)   0.1
  Negative             24 (28.6)       60 (71.4)                   

**Abbreviations:** MRM, modified radical mastectomy; BCS, breast-conserving surgery; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; *EZH2*, enhancer of zeste homolog 2.

###### 

Results of univariate and multivariate regression analyses of prognostic factors with *EZH2* expression

  Prognostic factors       Patients (n=100)       Univariate regression (95% CI)   Multivariate regression (95% CI)                                          
  ------------------------ ---------------------- -------------------------------- ---------------------------------- ------- -------- ------ ------ ------- -----
  Age (age of diagnosis)   ≤50 years (n=46)       1.88                             0.74                               4.77    0.1      0.52   0.19   1.38    0.1
  \>50 years (n=54)        Ref                    --                               --                                 --      --       --     --     --      
  Menopausal status        Premenopausal (n=71)   Ref                                                                         --       --     --     --      --
  Postmenopausal (n=29)    1.42                   0.54                             3.72                               0.4     --       --     --     --      
  Operation status         MRM (n=72)             Ref                              --                                         --       --     --     --      --
  BCS (n=28)               0.32                   0.12                             0.83                               0.19    --       --     --     --      
  Histologic grade         1 (n=13)               Ref                              --                                 --      --       --     --     --      --
  2 (n=60)                 2.17                   0.62                             7.63                               0.2     --       --     --     --      
  3 (n=12)                 4.28                   0.38                             47.62                              0.2     --       --     --     --      
  Vascular invasion        Positive (n=79)        0.86                             0.28                               2.64    0.7      --     --     --      --
  Negative (n=21)          Ref                    --                               --                                 --      --       --     --     --      
  Lymphatic invasion       Positive (n=34)        1.55                             0.58                               4.58    0.3      --     --     --      --
  Negative (n=66)          Ref                    --                               --                                 --      --       --     --     --      
  Tumor size               \<2 mm (n=13)          Ref                              --                                 --      --       --     --     --      --
  2--5 mm (n=72)           0.83                   0.20                             3.36                               0.8     --       --     --     --      
  ≥5 mm (n=15)             0.82                   0.14                             4.62                               0.8     --       --     --     --      
  Lymph node status        Positive (n=63)        8.44                             3.06                               23.33   \<0.05   --     --     --      --
  Negative (n=37)          Ref                    --                               --                                 --      --       --     --     --      
  Stage                    I (n=13)               Ref                              --                                 --      --       --     --     --      --
  II (n=60)                0.75                   0.18                             3.09                               0.7     --       --     --     --      
  III (n=12)               1.5                    0.20                             10.99                              0.6     --       --     --     --      
  IV (n=15)                0.82                   0.14                             4.62                               0.8     --       --     --     --      
  ER expression            Positive (n=86)        5.32                             0.66                               42.9    0.1      --     --     --      --
  Negative (n=14)          Ref                    --                               --                                 --      --       --     --     --      
  PR expression            Positive (n=89)        3.9                              0.47                               32.12   0.2      --     --     --      --
  Negative (n=11)          Ref                    --                               --                                 --      --       --     --     --      
  Ki-67 expression         Positive (n=47)        0.69                             0.28                               1.69    0.4      0.76   0.29   2.00    0.5
  Negative (n=53)          Ref                    --                               --                                 --      --       --     --     --      
  P53 expression           Positive (n=58)        0.52                             0.20                               1.35    0.18     0.48   0.17   1.3     0.1
  Negative (n=42)          Ref                    --                               --                                 --      --       --     --     --      
  HER2 expression          Positive (n=16)        2.8                              0.59                               13.26   0.1      2.16   0.48   11.49   0.3
  Negative (n=84)          Ref                    --                               --                                 --      --       --     --     --      

**Notes:** Lower, lower bound for 95% CI; upper, upper bound for 95% CI; variable adjusted for: age, sex, menopausal status, tumor size, lymph node status, vascular and lymphatic invasion, and tumor markers including ER, PR, Ki-67, P53, and HER2.

**Abbreviations:** MRM, modified radical mastectomy; BCS, breast-conserving surgery; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; *EZH2*, enhancer of zeste homolog 2; HR, hazard ratio; Ref, reference.

###### 

Results of Cox regression analysis of disease-free survival in patients with breast cancer

  Prognostic factors       Patients (n=100)   Univariate Cox regression (95% CI)   Multivariate Cox regression (95% CI)                                          
  ------------------------ ------------------ ------------------------------------ -------------------------------------- ------ ------ ------ -------- -------- ------
  Age (age of diagnosis)   ≤50 years (n=46)   1.2                                  0.35                                   4.14   0.7    5.38   0.34     85.16    0.2
  \>50 years (n=54)        Ref                --                                   --                                     --     --     --     --       --       
  Vascular invasion        Positive (n=79)    0.79                                 0.16                                   3.83   0.7    8.81   0.27     286.99   0.22
  Negative (n=21)          Ref                --                                   --                                     --     --     --     --       --       
  Lymphatic invasion       Positive (n=34)    0.81                                 0.23                                   2.84   0.7    0.07   0.00     0.951    0.05
  Negative (n=66)          Ref                --                                   --                                     --     --     --     --       --       
  Tumor size               \<2 mm (n=13)      Ref                                  --                                     --     --     --     --       --       --
  2--5 mm (n=72)           1.296              0.16                                 10.71                                  0.8    6.49   0.6    705.85   0.4      
  ≥5 mm (n=15)             1.58               0.93                                 26.89                                  0.7    0.29   0.00   24.06    0.5      
  Lymph node status        Positive (n=63)    2.05                                 0.44                                   9.64   0.36   --     --       --       --
  Negative (n=37)          Ref                --                                   --                                     --     --     --     --       --       
  Stage                    I (n=13)           Ref                                  --                                     --     --     --     --       --       --
  II (n=60)                1.07               0.12                                 9.71                                   0.9    0.26   0.11   6.04     0.4      
  III (n=12)               0.98               0.09                                 10.99                                  0.9    --     --     --       --       
  IV (n=15)                0.97               0.08                                 11.25                                  0.9    0.26   0.00   2.16     0.1      
  ER expression            Positive (n=86)    Ref                                  --                                     --     --     --     --       --       --
  Negative (n=14)          0.78               0.16                                 3.71                                   0.75   0.32   0.35   2.89     0.3      
  PR expression            Positive (n=89)    Ref                                  --                                     --     --     --     --       --       --
  Negative (n=11)          0.78               0.16                                 3.71                                   0.75   --     --     --       --       
  Ki-67 expression         Positive (n=47)    0.84                                 0.22                                   3.21   0.79   0.39   0.57     2.68     0.3
  Negative (n=53)          Ref                --                                   --                                     --     --     --     --       --       
  P53 expression           Positive (n=58)    0.59                                 0.14                                   2.51   --     0.25   0.26     2.34     0.2
  Negative (n=42)          Ref                --                                   --                                     --     --     --     --       --       
  HER2 expression          Positive (n=16)    0.86                                 0.18                                   4.08   --     1.66   0.24     11.65    0.6
  Negative (n=84)          Ref                --                                   --                                     --     --     --     --       --       

**Notes:** Lower, lower bound for 95% CI; upper, upper bound for 95% CI; variable adjusted for: age, sex, menopausal status, tumor size, lymph node status, vascular and lymphatic invasion, and tumor markers including ER, PR, Ki-67, P53, and HER2.

**Abbreviations:** MRM, modified radical mastectomy; BCS, breast-conserving surgery; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; *EZH2*, enhancer of zeste homolog 2; HR, hazard ratio; Ref, reference.

###### 

Results of Cox regression analysis of overall survival in patients with breast cancer

  Prognostic factors       Patients (n=100)   Univariate Cox regression (95% CI)   Multivariate Cox regression (95% CI)                                            
  ------------------------ ------------------ ------------------------------------ -------------------------------------- ------- ------ ------- -------- -------- ------
  Age (age of diagnosis)   ≤50 years (n=46)   7.48                                 0.64                                   84.20   0.10   --      --       --       --
  \>50 years (n=54)        Ref                --                                   --                                     --      --     --      --       --       
  Vascular invasion        Positive (n=79)    1.12                                 0.122                                  10.33   0.90   --      --       --       --
  Negative (n=21)          Ref                --                                   --                                     --      --     --      --       --       
  Lymphatic invasion       Positive (n=34)    1.26                                 0.25                                   6.32    0.70   1.02    0.08     12.76    0.90
  Negative (n=66)          Ref                --                                   --                                     --      --     --      --       --       
  Lymph node status        Positive (n=63)    1.20                                 0.22                                   6.71    0.80   1.42    0.12     16.37    0.70
  Negative (n=37)          Ref                --                                   --                                     --      --     --      --       --       
  ER expression            Positive (n=86)    Ref                                  --                                     --      --     --      --       --       --
  Negative (n=14)          0.59               0.10                                 3.44                                   0.50    0.01   0.00    2.232    0.09     
  PR expression            Positive (n=89)    Ref                                  --                                     --      --     --      --       --       --
  Negative (n=11)          0.53               0.06                                 4.85                                   0.50    4.34   0.09    215.40   0.46     
  Ki-67 expression         Positive (n=47)    2.29                                 0.38                                   13.90   0.36   9.26    0.46     186.50   0.11
  Negative (n=53)          Ref                --                                   --                                     --      --     --      --       --       
  P53 expression           Positive (n=58)    0.29                                 0.04                                   2.06    0.20   --      --       --       --
  Negative (n=42)          Ref                --                                   --                                     --      --     --      --       --       
  HER2 expression          Positive (n=16)    1.00                                 0.19                                   5.09    0.90   18.91   0.47     764.43   0.10
  Negative (n=84)          Ref                --                                   --                                     --      --     --      --       --       
  *EZH2* expression        Low (n=26)         Ref                                  --                                     --      --     --      --       --       --
  High (n=74)              2.76               0.32                                 24.17                                  0.35    5.87   0.43    80.52    0.10     

**Notes:** Lower, lower bound for 95% CI; upper, upper bound for 95% CI; variable adjusted for: age, sex, menopausal status, tumor size, lymph node status, vascular and lymphatic invasion, and tumor markers including ER, PR, Ki-67, P53, and HER2.

**Abbreviations:** MRM, modified radical mastectomy; BCS, breast-conserving surgery; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; *EZH2*, enhancer of zeste homolog 2; HR, hazard ratio; Ref, reference.
